◎ Sugi Atlas

Atlas / Disease / Impulse control disorder

Impulse control disorder

disease
On this page

Also known as ICDimpulse-control disorder

Summary

Impulse control disorder (MONDO:0001162) is a disease (an umbrella term covering 7 Mondo subtypes) with 4 GWAS associations across 4 studies and 67 clinical trials. Top therapeutic interventions include naltrexone, dronedarone, and escitalopram. A subtype of psychiatric disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 7 Mondo subtypes
  • GWAS associations: 4
  • Clinical trials: 67

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameimpulse control disorder
Mondo IDMONDO:0001162
DOIDDOID:10937
NCITC34723
SNOMED CT66347000
UMLSC0021122
MedGen5769
Is cancer (heuristic)no

Also known as: ICD · impulse-control disorder

Data availability: 4 GWAS associations (4 studies).

Disease family

This is a subtype of psychiatric disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › impulse control disorder

Related subtypes (13): sexual disorder, dissociative disorder, personality disorder, cognitive disorder, factitious disorder, substance-related disorder, somatoform disorder, mental disorder, eating disorder, enuresis, Alice in Wonderland syndrome, catatonia, body integrity dysphoria

Subtypes (7): kleptomania, intermittent explosive disorder, pyromania, Kluver-Bucy syndrome, pathological gambling, trichotillomania, primary polydipsia

Genetics & variants

GWAS landscape

4 GWAS associations across 4 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs1482679975e-07DAB1?2.1
rs23025326e-07PRKAG2?0.78
rs114660211e-06MEFV?2.6
rs784483341e-06PRKCE?0.48

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90481830Verma A20244,502444,779Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481829Verma A20242,111118,821Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90134329Weintraub D20221,9763,286Genetic prediction of impulse control disorders in Parkinson’s disease.
GCST90481828Verma A202477758,688Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic4

MAF distribution

BucketVariants
common (>=0.05)4
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant3
intergenic_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs148267997157838654C>T0.05intergenic_variantDAB15e-07Tier 4: intronic/intergenic
rs23025327151565219A>C0.05intron_variantPRKAG26e-07Tier 4: intronic/intergenic
rs11466021163249858A>G0.05intron_variantMEFV1e-06Tier 4: intronic/intergenic
rs78448334246047305A>G0.05intron_variantPRKCE1e-06Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 67.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified58
PHASE44
PHASE32
PHASE22
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00115011PHASE4COMPLETEDEscitalopram for the Treatment of Self-Injurious Skin Picking
NCT00118014PHASE4COMPLETEDSertraline and Habit Reversal in the Treatment of Patients With Trichotillomania
NCT01052831PHASE4COMPLETEDNaltrexone for Impulse Control Disorders in Parkinson’s Disease
NCT01683253PHASE4COMPLETEDRemission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
NCT00399698PHASE3COMPLETEDStudy to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
NCT03146130PHASE3UNKNOWNStudy of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders
NCT02934919PHASE2UNKNOWNEvaluation of Nalmefene in Impulse Control Disorders in Parkinson’s Disease: A Prospective Open Label Study
NCT03887429PHASE2COMPLETEDRestoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
NCT06639594PHASE1RECRUITINGFeasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study
NCT03357926Not specifiedRECRUITINGProspective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients
NCT04284800Not specifiedACTIVE_NOT_RECRUITINGMyocardial Injury in Patients With Cardiac Implantable Electronic Devices Undergoing Defibrillation Threshold Testing
NCT04416958Not specifiedRECRUITINGPacing to Maintain Physiologic Ventricular Activation
NCT04499326Not specifiedRECRUITINGImproving Patient Reported Outcome Measures in Catheter Ablation
NCT05072119Not specifiedRECRUITINGMonaldi Hospital Rhythm Registry
NCT05712057Not specifiedRECRUITINGNeurostimulation Versus Therapy for Problems With Emotions
NCT05835791Not specifiedRECRUITINGEND - VT Cohort Study
NCT06237868Not specifiedRECRUITINGrTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson’s Disease
NCT06485986Not specifiedRECRUITINGFrontosubthalamic Networks in Parkinson’s Disease.
NCT06498349Not specifiedRECRUITINGBilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
NCT06520150Not specifiedRECRUITINGEvaluation of the Effectiveness of Two Methods of Regional Anesthesia During S-ICD Implantation Procedure.
NCT06561919Not specifiedRECRUITINGSTIMPulseControl Ancillary Speech Study
NCT06923865Not specifiedNOT_YET_RECRUITINGControlled Evaluation of an Exercise Program for Overweight Adolescents
NCT07105241Not specifiedNOT_YET_RECRUITINGVirtual Reality in Electrophysiological Procedures and Device Implantation: the VR inEP Trial
NCT07342036Not specifiedRECRUITINGProspective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion
NCT07372196Not specifiedRECRUITINGLeft Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy
NCT07505394Not specifiedNOT_YET_RECRUITINGEfficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson’s Disease
NCT00652522Not specifiedCOMPLETEDAtrial Fibrillation Management in Congestive Heart Failure With Ablation
NCT00890461Not specifiedCOMPLETEDReconstruction of 12-Lead Electrogram From Intracardiac Signals From Defibrillators During or After Implantation
NCT01354236Not specifiedUNKNOWNMental Health Related to School Dropout in Luxembourg
NCT01430806Not specifiedUNKNOWNDronaderone to Prevent Recurrent Implantable Cardioverter Defibrillator (ICD) Shocks
NCT01454817Not specifiedCOMPLETEDA Study of Symptoms and Quality of Life in Patients With Implantable Cardiac Defibrillators (ICDs) and Their Caregivers
NCT01594112Not specifiedCOMPLETEDAbility of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.
NCT02052453Not specifiedCOMPLETEDICD-ON Registry: Periop Management of Cardiac Devices
NCT02087189Not specifiedCOMPLETEDTD01 Master Study (Safety and Efficacy Study)
NCT02319395Not specifiedCOMPLETEDBehavioural Addiction and Genetics in Parkinson’s Disease
NCT02693262Not specifiedCOMPLETEDComparing Rate Response With CLS Versus Accelerometer ICD Settings in Heart Failure Patients With BIOTRONIK CRT-Ds
NCT02713360Not specifiedCOMPLETEDScreening and Intervention Reducing Anxiety in Patients With Implanted Cardioverter Defibrillator (ICD)
NCT02722174Not specifiedCOMPLETEDFingerprinting of Impulsivity
NCT02755181Not specifiedCOMPLETEDfMRI in Impulsivity
NCT02796040Not specifiedUNKNOWNExploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson’s Disease: Study Using Tensor Diffusion Imaging and Tractography.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
NALTREXONE43
DRONEDARONE41
ESCITALOPRAM41
LEVODOPA41
NALMEFENE41
SERTRALINE41
CHEMBL178836101
CHEMBL35104201

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 21

This page pulls from 21 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncmedgenmeshmimmondomondochildmondoparentncitorphanetsctidumls